GLSI (Greenwich LifeSciences) Short Interest


GLSI Greenwich LifeSciences Inc GLSI
35 GF Score
Price $19.55
! 1 Warning Sign
View Full Analysis

What is Greenwich LifeSciences Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

GLSI vs SABS, SRZN, ZNTL: Short Interest Comparison

For the Biotechnology subindustry, Greenwich LifeSciences's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Greenwich LifeSciences Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Greenwich LifeSciences's Short Interest distribution charts can be found below:

* The bar in red indicates where Greenwich LifeSciences's Short Interest falls into.


GLSI
35GF Score
Greenwich LifeSciences Inc GLSI
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Greenwich LifeSciences Business Description

Address 3992 Bluebonnet Drive, Building 14, Stafford, TX, USA, 77477
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.
35GF Score

Get the complete analysis for GLSI

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$19.55
Price